CAMBRIDGE & LEXINGTON, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced positive preliminary results from a randomized, double-blind, placebo controlled phase 2a clinical study of ALKS 27 in patients with chronic obstructive pulmonary disease (COPD). In the study, single doses of ALKS 27 demonstrated a rapid onset of action and produced a significant improvement in lung function (p < .0001) over 24 hours compared to placebo. ALKS 27 is an inhaled formulation of trospium chloride using Alkermes' proprietary AIR® pulmonary delivery system.
